Moos, R. A. F. V., Müller, A., Hayoz, S., Mark, M. T., Fischer, S., Popescu, R. A., Rothschild, S. I., Fehr, M. K., Egger, C., Anchisi, S., Schmid, F., Zaman, K., Ackermann, C. J., Kugler, H., Bützberger, P., Uhlmann, C., Küng, M., Wyss, S., Templeton, A. J., Gillessen, S. (2026). Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1004